NASDAQ
RLYB

Rallybio Corp

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Rallybio Corp Stock Price

Vitals

Today's Low:
$5.17
Today's High:
$5.59
Open Price:
$5.29
52W Low:
$4.15
52W High:
$15.89
Prev. Close:
$5.35
Volume:
28732

Company Statistics

Market Cap.:
$204.50 million
Book Value:
3.685
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$0
Profit Margin:
0%
Return on Assets TTM:
-30.68%
Return on Equity TTM:
-49.13%

Company Profile

Rallybio Corp had its IPO on 2021-07-29 under the ticker symbol RLYB.

The company operates in the Healthcare sector and Biotechnology industry. Rallybio Corp has a staff strength of 45 employees.

Stock update

Shares of Rallybio Corp opened at $5.29 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $5.17 - $5.59, and closed at $5.53.

This is a +3.36% increase from the previous day's closing price.

A total volume of 28,732 shares were traded at the close of the day’s session.

In the last one week, shares of Rallybio Corp have increased by +2.22%.

Rallybio Corp's Key Ratios

Rallybio Corp has a market cap of $204.50 million, indicating a price to book ratio of 1.3859 and a price to sales ratio of 0.

In the last 12-months Rallybio Corp’s revenue was $0 with a gross profit of $0 and an EBITDA of $-74250000. The EBITDA ratio measures Rallybio Corp's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Rallybio Corp’s operating margin was 0% while its return on assets stood at -30.68% with a return of equity of -49.13%.

In Q2, Rallybio Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Rallybio Corp’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-1.87 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Rallybio Corp’s profitability.

Rallybio Corp stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.8282. Its price to sales ratio in the trailing 12-months stood at 0.

Rallybio Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$147.58 million
Total Liabilities
$8.05 million
Operating Cash Flow
$6.21 million
Capital Expenditure
$0
Dividend Payout Ratio
0%

Rallybio Corp ended 2024 with $147.58 million in total assets and $0 in total liabilities. Its intangible assets were valued at $147.58 million while shareholder equity stood at $139.26 million.

Rallybio Corp ended 2024 with $0 in deferred long-term liabilities, $8.05 million in other current liabilities, 4000.00 in common stock, $-196629000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $32.56 million and cash and short-term investments were $137.84 million. The company’s total short-term debt was $213,000 while long-term debt stood at $0.

Rallybio Corp’s total current assets stands at $146.83 million while long-term investments were $0.00 and short-term investments were $105.28 million. Its net receivables were $0 compared to accounts payable of $689000.00 and inventory worth $0.

In 2024, Rallybio Corp's operating cash flow was $6.21 million while its capital expenditure stood at $0.

Comparatively, Rallybio Corp paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$5.53
52-Week High
$15.89
52-Week Low
$4.15
Analyst Target Price
$20

Rallybio Corp stock is currently trading at $5.53 per share. It touched a 52-week high of $15.89 and a 52-week low of $15.89. Analysts tracking the stock have a 12-month average target price of $20.

Its 50-day moving average was $5.63 and 200-day moving average was $6.05 The short ratio stood at 24.05 indicating a short percent outstanding of 0%.

Around 561.2% of the company’s stock are held by insiders while 8669.6% are held by institutions.

Frequently Asked Questions About Rallybio Corp

The stock symbol (also called stock or share ticker) of Rallybio Corp is RLYB

The IPO of Rallybio Corp took place on 2021-07-29

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$38.97
0.95
+2.5%
$60.23
0.04
+0.07%
NIIT Limited (500304)
$117.15
18.24
+18.44%
$9.51
0.19
+2.04%
$9.06
0.17
+1.91%
$40.28
-0.39
-0.96%
$0.62
0
+0.29%
$804.6
-32.25
-3.85%
VGRDF (VGRDF)
$42.79
-0.69
-1.6%
$11.59
0.07
+0.61%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Rallybio Corporation, a clinical-stage biotechnology company, engages in identifying, accelerating, and development of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.

Address

234 Church Street, New Haven, CT, United States, 06510